Related Experiment Video

Updated: Mar 2, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and

Che-Kai Tsao1, Bobby Liaw2, Catherine He2

  • 1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA.

Therapeutic Advances in Medical Oncology
|May 12, 2017
PubMed

Insights

Renal cell cancer (RCC) remains a deadly malignancy. Recent advances, including anti-programmed cell death protein 1 therapies like nivolumab, offer new hope for improved treatment outcomes.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Renal cell cancer (RCC) is a leading cause of cancer death in the USA.
  • Anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors improved outcomes but therapeutic progress stalled.
  • Recent advances in understanding RCC biology and resistance have spurred new drug development.

Purpose of the Study:

  • To review recent advancements in renal cell cancer (RCC) treatment.
  • To highlight the impact of novel therapeutic strategies on disease outcomes.

Main Methods:

  • Literature review of recent clinical trials and research in RCC.
  • Analysis of the role of immunotherapy and targeted therapies in advanced RCC.

Main Results:

  • Anti-programmed cell death protein 1 (PD-1) immune checkpoint inhibitors, such as nivolumab, represent a significant breakthrough.
  • Nivolumab has paved the way for further clinical trials and the development of new therapies for RCC.

Conclusions:

  • A new era of drug development for renal cell cancer is underway.
  • Advances in understanding RCC biology are crucial for developing effective treatments.
Keywords:
clear cellimmunotherapyrenal cell carcinomatargeted therapiesvascular epidermal growth factor

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K